A conjugate comprising: a) a ligand for a glutathione transporter; wherein the ligand is selected from the group consisting of: glutathione, S-(p-bromobenzyl)glutathione, gamma-(L-gamma-azaglutamyl)-S-(p-bromobenzyl)-L-cysteinylglycin, S-butylglutathione, S-decylglutathione, glutathione reduced ethyl ester, glutathionesulfonic acid, S-hexylglutathione, S-lactoylglutathione, S-methylglutathione, S-(4-nitrobenzyl)glutathione, S-octylglutathione, S-propylglutathione, n-butanoyl gamma-glutamylcysteinylglycine, ethanoyl gamma-glutamylcysteinylglycine, hexanoyl gamma-glutamylcysteinylglycine, octanoyl gamma-glutamylcysteinylglycine, dodecanoyl gamma-glutamylcysteinylglycine, GSH monoisopropyl ester (N-(N-L-glutamyl-L-cysteinyl)glycine 1-isopropyl ester sulfate monohydrate) and glutathione derivatives of the formula I: wherein Z=CH 2 and Y=CH 2, or Z=O and Y = C=O; R 1 and R 2 are independently selected from the group consisting of: i) H, ii) linear or branched alkyl, iii) aralkyl, iv) cycloalkyl, v) heterocycles, vi) ethers or polyethers, and vii) where R 1 -R 2 together have 2-20C atoms and form a macrocycle with the remainder of formula I; R 3 is selected from the group consisting of H and CH 3; R4 is selected form the group consisting of 6-8C alkyl, benzyl, naphthyl and a therapeutically active compound; and, R5 is selected from the group consisting of H, phenyl, CH 3 - and CH 2 -phenyl; or, a pharmaceutically acceptable salt thereof. and, b) a liposome comprising a steroidal agent, wherein the ligand in a) is conjugated to the liposome in b), and wherein the steroidal agent is selected from the group consisting of hydrocortisone, cortisone acetate, prednisone, prednisolone, methylprednisolone, methylprednisolone acetate, methylprednisolone hemisuccinate, dexamethasone, betamethasone, triamcinolone, beclometasone, fludrocortisone acetate, fludrocortisone hemisuccinate, deoxycorticosterone acetate, deoxycorticosterone hemicussinate, and aldosterone. a) a ligand for a glutathione transporter; wherein the ligand is selected from the group consisting of: glutathione, S-(p-bromobenzyl)glutathione, gamma-(L-gamma-azaglutamyl)-S-(p-bromobenzyl)-L-cysteinylglycin, S-butylglutathione, S-decylglutathione, glutathione reduced ethyl ester, glutathionesulfonic acid, S-hexylglutathione, S-lactoylglutathione, S-methylglutathione, S-(4-nitrobenzyl)glutathione, S-octylglutathione, S-propylglutathione, n-butanoyl gamma-glutamylcysteinylglycine, ethanoyl gamma-glutamylcysteinylglycine, hexanoyl gamma-glutamylcysteinylglycine, octanoyl gamma-glutamylcysteinylglycine, dodecanoyl gamma-glutamylcysteinylglycine, GSH monoisopropyl ester (N-(N-L-glutamyl-L-cysteinyl)glycine 1-isopropyl ester sulfate monohydrate) and glutathione derivatives of the formula I: wherein Z=CH 2 and Y=CH 2, or Z=O and Y = C=O; R 1 and R 2 are independently selected from the group consisting of: i) H, ii) linear or branched alkyl, iii) aralkyl, iv) cycloalkyl, v) heterocycles, vi) ethers or polyethers, and vii) where R 1 -R 2 together have 2-20C atoms and form a macrocycle with the remainder of formula I; R 3 is selected from the group consisting of H and CH 3; R4 is selected form the group consisting of 6-8C alkyl, benzyl, naphthyl and a therapeutically active compound; and, R5 is selected from the group consisting of H, phenyl, CH 3 - and CH 2 -phenyl; or, a pharmaceutically acceptable salt thereof. and, i) H, ii) linear or branched alkyl, iii) aralkyl, iv) cycloalkyl, v) heterocycles, vi) ethers or polyethers, and vii) where R 1 -R 2 together have 2-20C atoms and form a macrocycle with the remainder of formula I; R4 is selected form the group consisting of 6-8C alkyl, benzyl, naphthyl and a therapeutically active compound; and, R5 is selected from the group consisting of H, phenyl, CH 3 - and CH 2 -phenyl; or, a pharmaceutically acceptable salt thereof. b) a liposome comprising a steroidal agent,